AMERICAN SHARED HOSPITAL SERVICES
AMSNYSEHealthcare · Services-Medical Laboratories · CA · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $28.1M | $28.3M | $21.3M | $19.7M | $17.6M | $17.8M |
| Operating income | −$3.6M | −$2.8M | $270,000 | $2.4M | $1.4M | −$9.5M |
| Net income | −$1.6M | $2.2M | $610,000 | $1.3M | $194,000 | −$7.1M |
| Total assets | $55.5M | $60.2M | $48.2M | $44.0M | $45.4M | $43.7M |
| Total liabilities | $27.8M | $30.2M | $21.9M | $18.3M | $21.2M | — |
| Equity | $24.0M | $25.2M | $22.6M | $21.6M | $19.9M | $19.3M |
| EPS (diluted) | $-0.23 | $0.33 | $0.10 | $0.21 | $0.03 | $-1.14 |
| Shares out. | 6.5M | 6.3M | 6.2M | 6.0M | 5.8M | 5.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −12.8%
- Net margin
- −5.5%
- Return on equity
- −6.5%
- Return on assets
- −2.8%
- Return on capital (ROCE)
- −11.2%
- Liabilities / assets
- 50.1%
- Debt / equity
- 1.16×
- Book value / share
- $3.73
- Revenue growth (YoY)
- −0.9%
- Net income growth (YoY)
- −171.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.05distress
- Accruals / assets
- −8.4%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2015
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2015
- NT 10-Qmissed a reporting deadline ↗Aug 14, 1995
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ruffle John FActivist (13D)Dec 16, 2025
- Stachowiak Raymond CActivist (13D)Dec 9, 2025
- Zucker Anita GActivist (13D)May 9, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Stachowiak Raymond COfficer — Executive Chairman | Mar 26, 2026 | Grant | 100,000 | $0.00 |
| Stachowiak Raymond COfficer — Executive Chairman | Jun 26, 2025 | Grant | 110,000 | $0.00 |
| Tagawa Craig KenjiOfficer — President | Apr 30, 2025 | Grant | 5,613 | $0.00 |
| Frech Raymond ScottOfficer — Chief Financial Officer | Dec 19, 2024 | Grant | 50,000 | $0.00 |
| Delanois GaryOfficer — Chief Operating Officer | Oct 14, 2024 | Grant | 120,000 | $0.00 |
| Stachowiak Raymond COfficer — Executive Chairman | Mar 22, 2024 | Grant | 120,000 | $0.00 |
| Stachowiak Raymond COfficer — Executive Chairman | Mar 28, 2023 | Grant | 120,000 | $0.00 |
| Tagawa Craig KenjiOfficer — President, CFO | Mar 7, 2023 | Grant | 10,827 | $0.00 |
| Stachowiak Raymond COfficer — CEO | May 31, 2022 | Option exercise | 2,000 | $2.70 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 118,040 | 1.0 | +9.5% |
| Apr 30, 2026 | 107,791 | 1.0 | +5482.1% |
| Apr 15, 2026 | 1,931 | 1.0 | +7.7% |
| Mar 31, 2026 | 1,793 | 1.0 | +107.0% |
| Mar 13, 2026 | 866 | 1.0 | -77.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Director / officer changeApr 24, 2026
- Results of operationsMar 31, 2026
- Entered a material agreementMar 19, 2026
- Prior financials not reliable (restatement)Jan 2, 2026
- Other material eventDec 16, 2025
- Results of operationsNov 13, 2025
- Results of operationsAug 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-QMay 14, 2026
- 8-KFORM 8-KMay 14, 2026
- DEFA14AFORM DEFA14AMay 7, 2026
- ARSFORM ARSApr 30, 2026
- DEFA14AFORM DEFA14AApr 30, 2026
- DEF 14AFORM DEF 14AApr 30, 2026
- 8-KFORM 8-KApr 24, 2026
- 4FORM 4Apr 15, 2026
- 10-KFORM 10-KMar 31, 2026
- 8-KFORM 8-KMar 31, 2026
- 8-KFORM 8-KMar 19, 2026
- 10-Q/AFORM 10-Q/AJan 16, 2026
- 8-KFORM 8-KJan 2, 2026
- SCHEDULE 13D/ADec 16, 2025
- 8-KFORM 8-KDec 16, 2025